HOMEwww.epgonline.orgDRUGSwww.epgonline.orgDISEASE KNOWLEDGEwww.epgonline.orgGUIDELINESwww.epgonline.orgCLINICAL TRIALSwww.epgonline.orgREGISTERwww.epgonline.orgSEARCH
Members
Why a doctor should
Username/Email

Password ()




EPG on Twitter EPG Online Twitter
EPG Online Blog EPG Online Blog
EPG Online Disease Knowledge Centres Feed Disease Knowledge
Recent UK Drug Updates Drug Updates
EPG Search
Search
Languages

APO-GO overview

Treatment of disabling motor fluctuations in patients with Parkinson's disease which persist after treatment with levodopa and/or other dopamine agonists.

banner_pass = 1

Please register to access disease diagnosis, patient management, physician tools.
By viewing the content of this web page you are both confirming your status as a healthcare professional and agreeing to our terms of use.

Change language Current language database: English
 
 
Related DrugsDrug Details
APO-GO
Drug Class Description :

Dopamine agonists (dopaminergics) .

Generic Name :

Apomorphine

Drug description :

Solution for injection in 2mL or 5mL ampoules.

Presentation :

Solution for injection, apomorphine hydrochloride 1.0% w/ v (10mg/mL).

Indications :

Treatment of disabling motor fluctuations in patients with Parkinson's disease which persist after treatment with levodopa and/or other dopamine agonists.

Adult Dosage :

For subcutaneous use by intermittent bolus injection. May also be administered as a continuous subcutaneous infusion by minipump. It is essential that the patient is established on domperidone, usually 20mg three times daily for at least two days prior to initiation of therapy.

Child Dosage :

Under 18 years, contraindicated.

Contra Indications :

Respiratory depression, dementia, hepatic insufficiency. hepatic insufficiency. Intermittent apomorphine treatment is not suitable for patients who have an 'on' response to levodopa which is marred by severe dyskinesia or dystonia. Known sensitivity to apomorphine or to any other ingredients of the product. Not recommended for use in women of child-bearing potential. Breastfeeding not recommended.

Special Precautions :

Renal, pulmonary or cardiovascular disease. Persons prone to nausea and vomiting. Elderly and/or debilitated patients. Pre-existing cardiac disease, patients taking vasoactive drugs such as antihypertensives, pre-existing postural hypotension.

Neuropsychiatric disturbance may be exacerbated by APO-go in some patients; there is also evidence from clinical studies that APO-go may improve these symtoms.

Interactions :

Neuroleptics, antihypertensives, cardiac active drugs.

Adverse Reactions :

Nausea and vomiting. Postural hypotension. Local subcutaneous injection site reactions including local induration and nodules (usually asymptomatic). Dyskinesia, neuropsychiatric disturbances. Transient sedation. Rarely, Coomb's positive haemolytic anaemia in patients treated with apomorphine and levodopa. Eosinophilia.

Manufacturer :

Britannia

Drug Availability :

(POM)

Drug Updated :

30 June 2009

Related Drugs - Neurodegenerative diseases
Male hypogonadism is the term used to describe decreased functional activity of the testes with diminished production and action of testosterone. Advancing Immunotherapy in Oncology The prognosis of patients with diabetes is improved by interventions that reduce HbA1C Prostate Cancer
New and updated Drugs
UK Drugs EPG Medical News Feed
Spanish Drugs EPG Medical News Feed
German Drugs EPG Medical News Feed
Norweigan Drugs EPG Medical News Feed
Netherlands Drugs EPG Medical News Feed
Swedish Drugs EPG Medical News Feed
French Drugs EPG French Drugs Feed
Portuguese Drugs EPG Portuguese Drugs Feed
Italian Drugs EPG Italian Drugs Feed

Atopic Dermatitis

Atopic Dermatitis

CONNECT

DISEASE CENTRES Disease Centres feed

AFFILIATE PARTNERS

QUICK SEARCH

GUIDELINES UK Drug Data Feed

DRUG DATA UK Drug Data Feed

REFERENCES